Antitumor activity of Fab′ and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: Effect on tumor cells in extranodal sites

Maria Ana Ghetie, James Richardson, Thomas Tucker, Diane Jones, Jonathan W. Uhr, Ellen S. Vitetta

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

The antitumor effects of two anti-CD22 ricin A chain-containing immunotoxin (IT) constructs were compared in mice with severe combined immunodeficiency disease with human Daudi cell tumors (SCID-Daudi mice). SCID-Daudi mice develop disseminated lymphoma that clinically resembles African Burkitt's lymphoma, i.e., extranodal disease including infiltration of the vertebral column and spinal canal. In the absence of treatment, the mean survival time of SCID-Daudi mice was 45.9 ± 4.3 days. The mice were given injections of a dose of IT equal to 40% of the 50% lethal dose. The ITs consisted of either IgG or Fab′ fragments of mouse anti-CD22 antibody coupled to deglycosylated ricin A chain (dgA). Both ITs were potent and specific and inhibited protein synthesis in Daudi cells in vitro by 50% at concentrations of 1.2 × 10-12 (IgG-dgA) and 1.3 × 10-11 M (Fab′-dgA). When administered to mice beginning 1 day after inoculation with tumor cells, both ITs extended the mean survival time, to 87.2 ± 18.9 days (IgG-dgA) or 57.9 ± 3.8 days (Fab′-dgA). The latter represented the killing of 2 logs of Daudi cells, and the former 4 logs. IgG antibody alone killed 1 log of tumor cells. The IgG-dgA had an antitumor effect even when administered 20-23 days after tumor inoculation. Gross and histological examinations of IT-treated tumor-bearing mice showed a marked decrease in the number and size of neoplastic foci in both lymphoid organs and extranodal sites.

Original languageEnglish (US)
Pages (from-to)5876-5880
Number of pages5
JournalCancer Research
Volume51
Issue number21
StatePublished - Nov 1 1991

Fingerprint

Immunotoxins
Severe Combined Immunodeficiency
Lymphoma
Immunoglobulin G
SCID Mice
Ricin
Burkitt Lymphoma
Neoplasms
Immunoglobulin Fab Fragments
Spinal Canal
Lethal Dose 50
Anti-Idiotypic Antibodies
Spine
anti-IgG
Injections
Antibodies
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Antitumor activity of Fab′ and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease : Effect on tumor cells in extranodal sites. / Ghetie, Maria Ana; Richardson, James; Tucker, Thomas; Jones, Diane; Uhr, Jonathan W.; Vitetta, Ellen S.

In: Cancer Research, Vol. 51, No. 21, 01.11.1991, p. 5876-5880.

Research output: Contribution to journalArticle

@article{3f8dd51ed4d84da2b81f3a50e968a9bb,
title = "Antitumor activity of Fab′ and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: Effect on tumor cells in extranodal sites",
abstract = "The antitumor effects of two anti-CD22 ricin A chain-containing immunotoxin (IT) constructs were compared in mice with severe combined immunodeficiency disease with human Daudi cell tumors (SCID-Daudi mice). SCID-Daudi mice develop disseminated lymphoma that clinically resembles African Burkitt's lymphoma, i.e., extranodal disease including infiltration of the vertebral column and spinal canal. In the absence of treatment, the mean survival time of SCID-Daudi mice was 45.9 ± 4.3 days. The mice were given injections of a dose of IT equal to 40{\%} of the 50{\%} lethal dose. The ITs consisted of either IgG or Fab′ fragments of mouse anti-CD22 antibody coupled to deglycosylated ricin A chain (dgA). Both ITs were potent and specific and inhibited protein synthesis in Daudi cells in vitro by 50{\%} at concentrations of 1.2 × 10-12 (IgG-dgA) and 1.3 × 10-11 M (Fab′-dgA). When administered to mice beginning 1 day after inoculation with tumor cells, both ITs extended the mean survival time, to 87.2 ± 18.9 days (IgG-dgA) or 57.9 ± 3.8 days (Fab′-dgA). The latter represented the killing of 2 logs of Daudi cells, and the former 4 logs. IgG antibody alone killed 1 log of tumor cells. The IgG-dgA had an antitumor effect even when administered 20-23 days after tumor inoculation. Gross and histological examinations of IT-treated tumor-bearing mice showed a marked decrease in the number and size of neoplastic foci in both lymphoid organs and extranodal sites.",
author = "Ghetie, {Maria Ana} and James Richardson and Thomas Tucker and Diane Jones and Uhr, {Jonathan W.} and Vitetta, {Ellen S.}",
year = "1991",
month = "11",
day = "1",
language = "English (US)",
volume = "51",
pages = "5876--5880",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Antitumor activity of Fab′ and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease

T2 - Effect on tumor cells in extranodal sites

AU - Ghetie, Maria Ana

AU - Richardson, James

AU - Tucker, Thomas

AU - Jones, Diane

AU - Uhr, Jonathan W.

AU - Vitetta, Ellen S.

PY - 1991/11/1

Y1 - 1991/11/1

N2 - The antitumor effects of two anti-CD22 ricin A chain-containing immunotoxin (IT) constructs were compared in mice with severe combined immunodeficiency disease with human Daudi cell tumors (SCID-Daudi mice). SCID-Daudi mice develop disseminated lymphoma that clinically resembles African Burkitt's lymphoma, i.e., extranodal disease including infiltration of the vertebral column and spinal canal. In the absence of treatment, the mean survival time of SCID-Daudi mice was 45.9 ± 4.3 days. The mice were given injections of a dose of IT equal to 40% of the 50% lethal dose. The ITs consisted of either IgG or Fab′ fragments of mouse anti-CD22 antibody coupled to deglycosylated ricin A chain (dgA). Both ITs were potent and specific and inhibited protein synthesis in Daudi cells in vitro by 50% at concentrations of 1.2 × 10-12 (IgG-dgA) and 1.3 × 10-11 M (Fab′-dgA). When administered to mice beginning 1 day after inoculation with tumor cells, both ITs extended the mean survival time, to 87.2 ± 18.9 days (IgG-dgA) or 57.9 ± 3.8 days (Fab′-dgA). The latter represented the killing of 2 logs of Daudi cells, and the former 4 logs. IgG antibody alone killed 1 log of tumor cells. The IgG-dgA had an antitumor effect even when administered 20-23 days after tumor inoculation. Gross and histological examinations of IT-treated tumor-bearing mice showed a marked decrease in the number and size of neoplastic foci in both lymphoid organs and extranodal sites.

AB - The antitumor effects of two anti-CD22 ricin A chain-containing immunotoxin (IT) constructs were compared in mice with severe combined immunodeficiency disease with human Daudi cell tumors (SCID-Daudi mice). SCID-Daudi mice develop disseminated lymphoma that clinically resembles African Burkitt's lymphoma, i.e., extranodal disease including infiltration of the vertebral column and spinal canal. In the absence of treatment, the mean survival time of SCID-Daudi mice was 45.9 ± 4.3 days. The mice were given injections of a dose of IT equal to 40% of the 50% lethal dose. The ITs consisted of either IgG or Fab′ fragments of mouse anti-CD22 antibody coupled to deglycosylated ricin A chain (dgA). Both ITs were potent and specific and inhibited protein synthesis in Daudi cells in vitro by 50% at concentrations of 1.2 × 10-12 (IgG-dgA) and 1.3 × 10-11 M (Fab′-dgA). When administered to mice beginning 1 day after inoculation with tumor cells, both ITs extended the mean survival time, to 87.2 ± 18.9 days (IgG-dgA) or 57.9 ± 3.8 days (Fab′-dgA). The latter represented the killing of 2 logs of Daudi cells, and the former 4 logs. IgG antibody alone killed 1 log of tumor cells. The IgG-dgA had an antitumor effect even when administered 20-23 days after tumor inoculation. Gross and histological examinations of IT-treated tumor-bearing mice showed a marked decrease in the number and size of neoplastic foci in both lymphoid organs and extranodal sites.

UR - http://www.scopus.com/inward/record.url?scp=0026355269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026355269&partnerID=8YFLogxK

M3 - Article

C2 - 1933855

AN - SCOPUS:0026355269

VL - 51

SP - 5876

EP - 5880

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 21

ER -